Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen sodium, quantity: 550 mg - tablet, film coated - excipient ingredients: purified water; microcrystalline cellulose; povidone; magnesium stearate; purified talc; titanium dioxide; hypromellose; macrogol 8000; indigo carmine - crysanal is indicated as an analgesic in acute migraine attacks, for the treatment of gout, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and for the relief of acute and/or chronic pain states in which there is an inflammatory component.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen sodium, quantity: 550 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; purified water; purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; indigo carmine - anaprox is indicated as an analgesic in acute migraine attacks, for the treatment of gout, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and for the relief of acute and/or chronic pain states in which there is an inflammatory component.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; povidone; magnesium stearate - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 500 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; iron oxide yellow; povidone - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - naproxen, quantity: 500 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; sodium starch glycollate; pregelatinised maize starch; maize starch; purified talc; colloidal anhydrous silica - treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis, ankylosing spondylitis; symptomatic treatment of primary dysmenorrhoea, relief of acute and/or chronic pain states in which there is an inflammatory component, and as an analgesic in acute migraine attack.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate; maize starch; purified talc; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis, ankylosing spondylitis; symptomatic treatment of primary dysmenorrhoea, relief of acute and/or chronic pain states in which there is an inflammatory component, and as an analgesic in acute migraine attack.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; purified water; sunset yellow fcf; magnesium stearate - rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and the relief of chronic pain states in which there is an inflammatory component.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate